ROHTO Pharmaceutical Posts Modest Q4 Operating Income Beat but Misses Consensus
ROHTO Pharmaceutical reported fourth-quarter operating income of 7.5 billion yen, beating internal forecasts but falling short of consensus. Consolidated sales and operating profit rose year-on-year, supported by stronger utilization and regional sales gains in Asia. Management provided fiscal 2027 guidance and raised the dividend ahead of a schedu…